GSK statement in response to the Prime Minister’s speech on life sciences

Issued: London UK

"The Government’s strategy for Life Sciences is a very important next step on the journey to make the UK the best place in the world to locate pharmaceutical investment. The actions on research and manufacturing will further strengthen the attractiveness of the UK and most importantly the results of the Innovation Review should ensure that the NHS is a stronger adopter of innovative medicines and technology, ensuring that all patients can benefit from cost-effective treatments and interventions approved by NICE.

"As a global company with very strong roots in the UK, GSK is positive about Britain’s future prospects as a place to research, develop, manufacture and commercialise our medicines. We are committed to working with Government to ensure the strategy that has been set out today will deliver on the promise to make the UK a world class environment for life sciences."

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2010.